Stay updated with breaking news from Lung Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The US Food and Drug Administration has granted early approval to Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of patients age 12 years and older with severe asthma.
AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal...